Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15174366 | 0.88 | KMT2A (0.44) | KMT2AMEN1LMNAALDH1A1GAA | |
| SCHEMBL28063618 | 0.84 | — | — | |
| SCHEMBL300143 | 0.82 | KMT2A (0.41) | KMT2AMEN1LMNAALDH1A1GAA | |
| SCHEMBL24736445 | 0.80 | KMT2A (0.47) | KMT2AMEN1LMNAALDH1A1GAA | |
| SCHEMBL232222 | 0.80 | KMT2A (0.47) | KMT2AMEN1LMNAALDH1A1GAA | |
| SCHEMBL8737569 | 0.80 | KMT2A (0.47) | KMT2AMEN1LMNAALDH1A1GAA | |
| SCHEMBL11480149 | 0.78 | KMT2A (0.46) | KMT2AMEN1LMNAALDH1A1GAA | |
| SCHEMBL18922322 | 0.78 | KMT2A (0.46) | KMT2AMEN1LMNAALDH1A1GAA | |
| SCHEMBL3094796 | 0.78 | KMT2A (0.46) | KMT2AMEN1LMNAALDH1A1GAA | |
| SCHEMBL4856749 | 0.78 | KMT2A (0.46) | KMT2AMEN1LMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | claimed |
| US-20170157056-A9 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2017-06-08 | — | — | US | claimed |
| US-20160113879-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2016-04-28 | — | — | US | claimed |
| US-20150265707-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | claimed |
| EP-2887933-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XenoPort, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| EP-2887934-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XenoPort, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| EP-2887935-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XenoPort, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| EP-2854795-A1 | TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE | XenoPort, Inc. (US) | 2015-04-08 | — | — | EP | claimed |
| US-20140364604-A1 | METHOD OF MAKING MONOMETHYL FUMARATE | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2014-12-11 | — | — | US | claimed |
| US-20140348914-A9 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-11-27 | — | — | US | claimed |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-11-27 | — | — | US | claimed |
| US-20140348915-A9 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-11-27 | — | — | US | claimed |
| US-20140065211-A1 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| WO-2014031844-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| WO-2014031892-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| WO-2014031894-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20140056978-A1 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-20130324539-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | WILSHIRE PHARMACEUTICALS, INC. | 2013-12-05 | — | — | US | claimed |
| WO-2013181451-A1 | TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE | XENOPORT, INC. (US) | 2013-12-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140348915-A9 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof | FH, MGMT, BHMT2 | KMT2A 422/4885MEN1 1350/4885LMNA 4831/4885 |
| US-20140348914-A9 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof | FH, MGMT, BHMT2 | KMT2A 422/4885MEN1 1350/4885LMNA 4831/4885 |
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | KMT2A 578/4885MEN1 1212/4885LMNA 2857/4885 |
| US-20160113879-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | KMT2A 434/4885MEN1 1773/4885LMNA 4876/4885 |
| US-20150265707-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KMT2A 1771/4885MEN1 82/4885LMNA 2691/4885 |
| US-20170157056-A9 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | KMT2A 434/4885MEN1 1773/4885LMNA 4876/4885 |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | KMT2A 578/4885MEN1 1212/4885LMNA 2857/4885 |
| US-20140364604-A1 | METHOD OF MAKING MONOMETHYL FUMARATE | FH, HNMT, FPGS | KMT2A 433/4885MEN1 1689/4885LMNA 4040/4885 |
| US-20140065211-A1 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof | FH, MGMT, BHMT2 | KMT2A 422/4885MEN1 1350/4885LMNA 4831/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | KMT2A 578/4885MEN1 1212/4885LMNA 2857/4885 |
| US-20140056978-A1 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof | FH, MGMT, BHMT2 | KMT2A 422/4885MEN1 1350/4885LMNA 4831/4885 |
| US-20130324539-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | MGMT, FH, SI | KMT2A 376/4885MEN1 1323/4885LMNA 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.